REGN FY 2008 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$78B

FY 2008 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$238M+90.7% YoY

Gross Profit

$226M94.9% margin

Operating Income

-$90M-37.7% margin

Net Income

-$83M-34.7% margin

EPS (Diluted)

$-1.05

Cash Flow

Operating Cash Flow

-$89M

Free Cash Flow

-$124M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$670M

Total Liabilities

$251M

Stockholders' Equity

$419M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$238M	$125M	+90.7%
Gross Profit	$226M	$0	—
Operating Income	-$90M	-$114M	+21.5%
Net Income	-$83M	-$106M	+21.7%